trientine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2738 112-24-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • triethylene tetramine
  • triethylene tetramine dihydrochloride
  • trientine
  • trien
  • 1,8-Diamino-3,6-diazaoctane
  • trientine hydrochloride
  • triethylenetetramine
  • trientine dihydrochloride
  • trientine tetrahydrochloride
  • trientine HCl
An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
  • Molecular weight: 146.24
  • Formula: C6H18N4
  • CLOGP: -2.37
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 76.10
  • ALOGS: -0.73
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.45 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 92.50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
July 25, 2019 EMA Univar BV
Nov. 8, 1985 FDA ATON

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC A16AX12 ALIMENTARY TRACT AND METABOLISM
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
Various alimentary tract and metabolism products
FDA MoA N0000175472 Metal Chelating Activity
FDA EPC N0000175473 Metal Chelator
MeSH PA D002614 Chelating Agents
MeSH PA D064449 Sequestering Agents
CHEBI has role CHEBI:166831 copper chelate

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Wilson's disease indication 88518009
Plaque psoriasis indication 200965009
Scalp psoriasis indication 238608008
Renal cell carcinoma indication 702391001 DOID:4450
Psoriasis off-label use 9014002 DOID:8893
Hypocalcemia contraindication 5291005
Acute hemorrhage contraindication 8573003
Congenital ichthyosis of skin contraindication 13059002
Hyperbilirubinemia contraindication 14783006 DOID:2741
Myocardial infarction contraindication 22298006 DOID:5844
Hypervitaminosis D contraindication 27712000 DOID:9971
Proteinuria contraindication 29738008 DOID:576
Torsades de pointes contraindication 31722008
Guttate psoriasis contraindication 37042000
Gastrointestinal fistula contraindication 37831005
Hypertensive disorder contraindication 38341003 DOID:10763
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Gastrointestinal perforation contraindication 51875005
Hepatic failure contraindication 59927004
Diarrhea contraindication 62315008
Hypercalcemia contraindication 66931009 DOID:12678
Disorder of calcium metabolism contraindication 71638002 DOID:10575
Hypercalciuria contraindication 71938000
Gastrointestinal hemorrhage contraindication 74474003
Pancreatitis contraindication 75694006 DOID:4989
Iron deficiency anemia contraindication 87522002
Prolonged QT interval contraindication 111975006
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Angina pectoris contraindication 194828000
Pustular psoriasis contraindication 200973000
Drug-induced hepatitis contraindication 235876009
Telangiectasia disorder contraindication 247479008
Cerebral hemorrhage contraindication 274100004
Pregnancy, function contraindication 289908002
Thromboembolic disorder contraindication 371039008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Surgical procedure contraindication 387713003
Cardiovascular event risk contraindication 395112001
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006
UGT1A1*28 polymorphism contraindication 430235005
Congenital long QT syndrome contraindication 442917000
Hypertensive urgency contraindication 443482000
Acute Thromboembolic Stroke contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.93 Basic
pKa2 6.93 Basic
pKa3 6.19 Basic
pKa4 5.58 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Carbonic anhydrase 3 Enzyme Ki 4.32 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 4.19 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 4 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 4.46 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 4.41 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 4.24 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 4.42 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 4.31 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 4.35 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 4.37 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 4.92 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 4.28 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 4.23 CHEMBL

External reference:

IDSource
4019956 VUID
N0000148041 NUI
D00736 KEGG_DRUG
38260-01-4 SECONDARY_CAS_RN
4017951 VANDF
4019956 VANDF
C0040976 UMLSCUI
CHEBI:39501 CHEBI
104 PDB_CHEM_ID
CHEMBL609 ChEMBL_ID
DB06824 DRUGBANK_ID
CHEMBL3989777 ChEMBL_ID
CHEMBL1200783 ChEMBL_ID
D014266 MESH_DESCRIPTOR_UI
5565 PUBCHEM_CID
4664 INN_ID
SJ76Y07H5F UNII
10798 RXNORM
269581 MMSL
36945 MMSL
5623 MMSL
d01416 MMSL
001093 NDDF
004541 NDDF
018063 NDDF
109102003 SNOMEDCT_US
109103008 SNOMEDCT_US
1149496005 SNOMEDCT_US
373456001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Syprine HUMAN PRESCRIPTION DRUG LABEL 1 0187-2120 CAPSULE 250 mg ORAL NDA 23 sections
TRIENTINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0527-4068 CAPSULE 250 mg ORAL ANDA 19 sections
Trientine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-4910 CAPSULE 250 mg ORAL ANDA 23 sections
Trientine Hydrochloride Human Prescription Drug Label 1 16571-810 CAPSULE 250 mg ORAL ANDA 20 sections
Trientine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43598-459 CAPSULE 250 mg ORAL ANDA 19 sections
Trientine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 49884-060 CAPSULE 250 mg ORAL ANDA 16 sections
Trientine hydrochloride Human Prescription Drug Label 1 64980-450 CAPSULE 250 mg ORAL ANDA 20 sections
Trientine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68475-200 CAPSULE 250 mg ORAL ANDA 20 sections
Trientine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68682-212 CAPSULE 250 mg ORAL NDA authorized generic 23 sections
Trientine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 69238-1545 CAPSULE, GELATIN COATED 250 mg ORAL ANDA 19 sections
Trientine hydrochloride Human Prescription Drug Label 1 69539-078 CAPSULE 250 mg ORAL ANDA 20 sections
Trientine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70710-1203 CAPSULE 250 mg ORAL ANDA 20 sections
Trientine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70771-1438 CAPSULE 250 mg ORAL ANDA 1 sections
Trientine hydrochloride Human Prescription Drug Label 1 72205-008 CAPSULE 250 mg ORAL ANDA 20 sections